Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triumph-01: Phase I/II study of GLS-012 monotherapy in advanced solid tumors after standard treatment failure
CTR20221969Phase 2Active
- Sponsor
- Guangzhou Gloria Biosciences Co., Ltd.
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of brivestobart in Nonhematologic neoplasms (2 arms), sponsored by Guangzhou Gloria Biosciences Co., Ltd. Primary endpoints: Dose-limiting toxicity, Maximum tolerated dose and 1 more. Started Nov 2022; status: active.
02
Drugs
brivestobart
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20221969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221969.